Company profile: Orthofix
1.1 - Company Overview
Company description
- Provider of medical devices and digital solutions for spine procedures (alignment, disc height improvement, nerve decompression, instability correction); biologics including viable-cell allografts, structural allografts, synthetic bone grafts, and amniotic membranes; PEMF bone growth therapy for spinal fusion and nonunion fractures; and the Fitbone motorized intramedullary nail for femur/tibia transport or lengthening.
Products and services
- Biologics: Orthofix supplies cellular-based products—viable cell allografts, structural allografts, synthetic bone grafts, and amniotic membranes—engineered to enhance bone healing across orthopedic applications
- Spine Procedures: Orthofix delivers surgical-grade devices for spinal alignment, disc height improvement, nerve decompression, and instability correction utilized across various spine procedures
- Bone Growth Therapy: Orthofix produces PEMF-based devices that promote spinal fusion and heal nonunion fractures, applying pulsed electromagnetic fields to support bone repair
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orthofix
Acousia Therapeutics
HQ: Germany
Website
- Description: Provider of small-molecule therapeutics for sensorineural hearing loss, with expertise in identifying and developing drug candidates to enhance and preserve natural hearing. Products include ACOU085, an etiology-agnostic otoprotective candidate preventing chemotherapy-induced hearing loss and sensory hair cell death, and ACOU082, an oral Kv7.4 activator to enhance natural hearing and protect against age-related loss.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acousia Therapeutics company profile →
Aurion Biotech
HQ: United States
Website
- Description: Provider of clinical-stage cell therapies to treat ocular diseases, developing a platform targeting leading forms of blindness. Based in Seattle, Boston and Tokyo, candidates include Vyznova, a cell therapy for corneal endothelial cell dystrophies using cultured cells from a single donor, and AURN001, a combination cell therapy for corneal edema involving intracameral injection of neltependocel and Y-27632.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurion Biotech company profile →
Tissue Genesis
HQ: United States
Website
- Description: Provider of advanced tissue engineering and cell therapy solutions, offering the Icellator2 automated device to extract adult stem cells from adipose tissue for high-yield SVF cells in about an hour, and the sterile, single-use Cell Icellation Kit for efficient SVF isolation with the Icellator2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tissue Genesis company profile →
Coeptis Therapeutics
HQ: United States
Website
- Description: Provider of cell therapy platforms: SNAP-CAR uses monoclonal antibodies with benzyl guanine linkers for tunable oncology or autoimmune treatment; GEAR-NK is a modified NK therapy co-administered with targeted antibodies; cord blood-derived HSPCs generate NK cells; and an unmodified NK program enables allogeneic therapy without HLA matching, currently in Phase 1 for anti-viral treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coeptis Therapeutics company profile →
Amorcyte
HQ: United States
Website
- Description: Provider of cell therapy products for cardiovascular disease, including lead candidate AMR—001 to prevent major adverse cardiac events following acute myocardial infarction (AMI); Phase I clinical trials have demonstrated feasibility, safety and biologic activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amorcyte company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orthofix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orthofix
2.2 - Growth funds investing in similar companies to Orthofix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orthofix
4.2 - Public trading comparable groups for Orthofix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →